EMA Authorised: Mevlyq (Eribulin mesylate) — YES Pharmaceutical Development Services GmbH

View source ↗

Summary

The EMA authorised Mevlyq (eribulin mesylate) for breast cancer and liposarcoma, with marketing authorisation holder YES Pharmaceutical Development Services Gmb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Liposarcoma

Drugs mentioned

• Mevlyq (eribulin mesylate)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Liposarcoma. MAH: YES Pharmaceutical Development Services GmbH. Decision date: 14/10/2024